---
title: "aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295273774.md"
description: "aTyr Pharma reported a narrowed Q2 2026 net loss of $10.3M, driven by reduced R&D spending on efzofitimod. The company announced a 60% workforce reduction to cut $13M in annual expenses ahead of a planned Phase 3 study for pulmonary sarcoidosis. Although the EFZO-FIT trial missed its primary endpoint, it showed quality-of-life improvements. Additionally, aTyr is advancing preclinical candidate ATYR0101 and expanding its discovery platform."
datetime: "2026-08-07T20:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295273774.md)
  - [en](https://longbridge.com/en/news/295273774.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295273774.md)
generator: "portal-rs"
---

# aTYR PHARMA INC 2Q 2026: Net loss $(10.3M), EPS $(0.11) — 10-Q Summary

aTyr Pharma reported second-quarter 2026 results with a reduced net loss versus the year-ago quarter, driven primarily by lower research-and-development spending related to efzofitimod as the company prepares for a planned Phase 3 program.

**Financial Highlights**

-   Net income: Net loss attributable to aTyr Pharma, Inc. of $(10.3M) for 2Q 2026 vs $(19.5M) in 2Q 2025.
-   Diluted EPS: Net loss per share, basic and diluted of $(0.11) for 2Q 2026 vs $(0.22) in 2Q 2025.
-   Commentary: Reduced R&D spend (primarily lower efzofitimod costs) drove the year‑over‑year improvement in net loss for the quarter.

**Business Highlights**

-   Phase 3 program update: Plans to initiate a new global Phase 3 FVC‑focused study in moderate‑to‑severe pulmonary sarcoidosis following FDA Type C feedback.
-   EFZO‑FIT results & impact: The Phase 3 EFZO‑FIT trial missed its steroid‑reduction primary endpoint but showed nominal improvements in KSQ‑Lung, fatigue and quality‑of‑life measures.
-   Operational restructuring: Announced a workforce reduction of approximately 60% to conserve cash and reduce roughly $13M of annual operating expenses ahead of the planned Phase 3.
-   Pipeline & discovery momentum: Advancing preclinical candidate ATYR0101 (IND‑enabling) and expanding its tRNA synthetase discovery platform for fibrosis and inflammation programs.

Original SEC Filing: aTYR PHARMA INC \[ ATYR \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [aTyr Pharma Q2 FY26 net loss narrows to $10.31 million](https://longbridge.com/en/news/295272329.md)
- [FLUX: Revenue fell 37% in 2026, with ongoing losses and liquidity risks raising going concern doubts](https://longbridge.com/en/news/296531754.md)
- [AI isn’t close to curing cancer. This startup says it knows what it will take.](https://longbridge.com/en/news/296352961.md)
- [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**